Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 72Etoposide 29Daunorubicin 25Filgrastim 24Idarubicin 22Mitoxantrone 21Busulfan 21Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 20fludarabine phosphate 18Gemtuzumab 13Antilymphocyte Serum 12tipifarnib 11Radiotherapy 11Gene Expression Profiling 10Flow Cytometry 10Cyclosporine 10Clofarabine 10sargramostim 9Methotrexate 9Azacitidine 8aldesleukin 6Vorinostat 6Topotecan 6Tacrolimus 6valspodar 5alvocidib 5Whole-Body Irradiation 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Megakaryoblastic, Acute × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡